title: 5,5-Diphenyl-2-thiohydantoin-N10 (DPTH-N10) suppresses proliferation of cultured colon cancer cell line COLO-205 by inhibiting DNA synthesis and activating apoptosis.
abstract: The aim of this study was to investigate the potential applications of 5,5-diphenyl-2-thiohydantoin-N10 (DPTH-N10) in the treatment of human colon cancer. Subcultured human colon cancer cell line, COLO-205, was used for examining the antiproliferation effect of DPTH-N10 on colon cancer. Thymidine incorporation and cell count were conducted to examine the antiproliferation effect of DPTH-N10. Western blot analysis was performed to examine the protein levels of cell cycle-related proteins. DNA fragmentation assay was performed to examine the occurrence of apoptosis. DPTH-N10 at a range of concentrations (0-30 microM) inhibits the proliferation but did not cause the cell death of COLO-205, indicating that it may have an inhibitory effect on the cell proliferation in COLO-205. The apoptosis was observed in COLO-205 when the DPTH-N10 concentrations were higher than 30 muM. Western blot analysis showed that the protein level of the cell cycle inhibitory protein, p21, in COLO-205 increased after DPTH-N10 treatment. Immunoprecipitation showed that the formation of the cyclin-dependent kinase (CDK)2-p21 complex was increased in the DPTH-N10-treated COLO-205. Kinase assay further demonstrated that the CDK2 activity was decreased in the DPTH-N10-treated COLO-205. DPTH-N10 caused growth inhibition in COLO-205 by inhibiting DNA synthesis and activating apoptosis. The findings from our previous in vitro studies in DPTH-N10-induced anti-angiogenic effect and from the present in vitro studies in DPTH-N10-induced antiproliferation effect on colon cancer cell line strongly suggest the potential applications of DPTH-N10 in the treatment of human colon cancer.
authors.affiliation: Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan.
authors.forename: Tong-Sheng
authors.initials: TS
authors.lastname: Lee
authors.forename: Li-Ching
authors.initials: LC
authors.lastname: Chen
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liu
authors.forename: Jender
authors.initials: J
authors.lastname: Wu
authors.forename: Yu-Chih
authors.initials: YC
authors.lastname: Liang
authors.forename: Wen-Sen
authors.initials: WS
authors.lastname: Lee
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000187:drug effects / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis*; D053938:DNA Fragmentation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010672:Phenytoin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: C552285:5,5-diphenyl-2-thiohydantoin-N10; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D050759:Cyclin-Dependent Kinase Inhibitor p21; D010672:Phenytoin; D004247:DNA
references.citation: Cell. 1994 Nov 18;79(4):573-82
references.pmid: 7954824
references.citation: J Biol Chem. 1996 Jun 28;271(26):15782-6
references.pmid: 8663132
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: Int J Cancer. 2004 Aug 10;111(1):51-9
references.pmid: 15185342
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: Mol Carcinog. 2002 Sep;35(1):21-8
references.pmid: 12203364
references.citation: Proc Soc Exp Biol Med. 1988 Jun;188(2):173-6
references.pmid: 3375264
references.citation: Genes Dev. 1995 May 15;9(10):1149-63
references.pmid: 7758941
references.citation: Cancer Lett. 2008 Nov 28;271(2):294-305
references.pmid: 18649995
references.citation: Curr Top Med Chem. 2005;5(1):3-14
references.pmid: 15638774
references.citation: Nat Med. 1997 Nov;3(11):1233-41
references.pmid: 9359698
references.citation: Biochem Pharmacol. 2004 Jan 1;67(1):67-75
references.pmid: 14667929
references.citation: Biochem Pharmacol. 2003 Jul 15;66(2):263-71
references.pmid: 12826268
references.citation: Biochem Pharmacol. 2004 May 15;67(10):1907-16
references.pmid: 15130767
references.citation: Nature. 1995 Mar 9;374(6518):131-4
references.pmid: 7877684
references.citation: Cell. 1994 Oct 21;79(2):315-28
references.pmid: 7525077
references.citation: Cell. 1993 Nov 19;75(4):817-25
references.pmid: 8242752
references.citation: Nat Med. 1997 Sep;3(9):1005-8
references.pmid: 9288727
references.citation: Epilepsia. 1992 Jul-Aug;33(4):729-35
references.pmid: 1628591
references.citation: Mol Cell Endocrinol. 2004 Jan 15;213(2):173-9
references.pmid: 15062565
references.citation: Vascul Pharmacol. 2008 Feb-Mar;48(2-3):138-42
references.pmid: 18295547